Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press62410.36691/RJA624ArticlesСтатьиResearch ArticleTHE ROLE OF NEBULIZED BECLOMETHASONE DIPROPIONATE IN THE TREATMENT OF BRONCHIAL ASTHMAЗНАЧЕНИЕ НЕБУЛАЙЗЕРНОЙ ТЕРАПИИ БЕКЛОМЕТАЗОНА ДИПРОПИОНАТОМ ПРИ БРОНХИАЛЬНОЙ АСТМЕAvdeevS NАвдеевСергей Николаевичserg_avdeev@list.ruInstitute of PulmonologyФГБУ «НИИ пульмонологии» ФМБА России15122013106NO6 (2013)№6 (2013)415010032020Copyright ©; 2013, Pharmarus Print MediaCopyright ©; 2013, Фармарус Принт Медиа2013Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/624

Beclomethasone dipropionate (BDP, Clenil UDV) is a well-studied inhaled corticosteroid for the treatment of patients with bronchial asthma (BA). Randomized controlled trials have shown that nebulized therapy with BDP was similar in its efficacy and safety to inhalation therapy with budesonide or fluticasone. Preferred patients for the treatment with nebulized BDP are elderly patients with asthma, unable to correctly perform inhalation with portable devices, patients with steroid-dependent asthma, and patients with a temporary loss of asthma control.

Ингаляционный глюкокортикостероид беклометазона дипропионат (БДП, Кленил УДВ) является хорошо изученным препаратом для терапии пациентов с бронхиальной астмой (БА). В рандомизированных контролируемых исследованиях показано, что небулайзерная терапия БДП по своей эффективности и безопасности сравнима с небулайзерной терапией будесонидом и флутиказоном. Терапия небулизированным БДП особенно показана пожилым пациентам с БА, не способным правильно пользоваться другими ингаляционными устройствами, пациентам со стероидозависимой БА, а также пациентам с временной утратой контроля над БА.

asthmainhaled corticosteroidsbeclomethasone dipropionatenebulized therapyбронхиальная астмаингаляционные глюкокортикостероидыбеклометазона дипропионатнебулайзерная терапияGlobal Initiative for Asthma. Global strategy for asthma management and prevention. Available from www.ginasthma.org. Date last updated. 2012.Bateman E.D., Hurd S.S., Barnes P.J. et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008, v. 31, p. 143-178.Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004, v. 59, p. 469-478.Weiss K.B., Sullivan S.D., Lyttle C.S. Trends in the cost of illness for asthma in the United States, 1985—1994. J. Allergy Clin. Immunol. 2000, v. 106, p. 493-499.Asthma insight and management. 2009. Available at: http:// www.takingaimatasthma. com/survey-results.html. Accessed March 9, 2010.Fuhlbrigge A.L., Adams R.J., Guilbert T.W. et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am. J. Respir. Crit. Care Med. 2002, v. 166, p. 1044-1049.Gibson P.G., Powell H., Ducharme F.M. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J. Allergy Clin. Immunol. 2007, v. 119, p. 344-350.Lai C.K., De Guia T.S., Kim Y.Y. et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J. Allergy Clin. Immunol. 2003, v. 111, p. 263-268.Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000, v. 16, p. 802-807.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004, v. 170, p. 836-844.Melani A.S., Canessa P., Coloretti I. et al. Inhaler mishandling is very common in patients with chronic airflow obstruction and long-term home nebuliser use. Respir. Med. 2012, v. 106, p. 668-676.Cochrane M.G., Bala M.V., Downs K.E. et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest. 2000, v. 117, p. 542-550.Huchon G. Metered dose inhalers part and present: advantages and limitations. Eur. Respir. Rev. 1997, v. 7, 41, p. 26-28.Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 2002, v. 96, p. 293-304.Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. Мед. Журн. 2002, 10 (№ 5), c. 255-261.Muers M.F. Overview of nebulizer treatment. Thorax. 1997, v. 52 (Suppl. 2), p. S25-S30.Boe J., Dennis J.H., O’Driscoll B.R. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 2001, v. 18, p. 228-242.Dennis J.H. A review of issues relating to nebulizer standards. J. Aerosol. Med. 1998, v. 11, p. 73-79.Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care. 2002, v. 47, p. 1406-1418.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011, v. 37, p. 1308-1331.Terzano C., Allegra L. Importance of drug delivery system in steroid aerosol therapy via nebulizer. Pulm. Pharmacol. Ther. 2002, v. 15, p. 449-454.Yoshiyama Y., Yazaki T., Arai M. et al. The nebulization of budesonide suspensions by a newly designed mesh nebulizer. In: Dalby R.N., Byron P. R., Peart J. and Farr S.F., eds. Respiratory drug delivery VIII. Raleigh: Davis Horwood. 2002, p. 487-489.Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest. 2005, v. 127, p. 335-371.British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax. 1997, v. 52 (Suppl. 2), p. S1-S24.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2006, National Institutes of Health/WHO. Available from http:// www.goldcopd.com/.ERS Task Force. European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 2001, v. 18, p. 228-242.WHO model list of essential medicines, 15th list. World Health Organization Geneva March 2007. 2007 [cited 2009 19 February]; Available from http://www.who.int/medicines/ publications/08_ENGLISH_indexFINAL_EML15.pdf.Abdullah A.K., Khan S. Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. J. Asthma. 2007, v. 44, p. 1-12.Nicolini G., Cremonesi G., Melani A.S. Inhaled corticosteroid therapy with nebulized beclometasone dipropionate. Pulm. Pharmacol Therap. 2010, v. 23, p. 145-155.Kelly H.W. Comparison of inhaled corticosteroids: an update. Ann. Pharmacother. 2009, v. 43, p. 519-527.Rohatagi S., Appajosyula S., Derendorf H. et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. 2004, v. 44, p. 37-47.Colice G.L. Pharmacodynamic and pharmacokinetic considerations in choosing an inhaled corticosteroid. Treat. Respir. Med. 2006, v. 5, p. 245-253.Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006, v. 28, p. 1042-1050.Daley-Yates P.T., Price A.C., Sisson J.R. et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol. 2001, v. 51, p. 400-409.Baptist A.P., Reddy R.C. Inhaled corticosteroids for asthma: are they all the same? J. Clin. Pharm. Ther. 2009, v. 34, p. 1-12.Terzano C., Petroianni A., Parola D., Ricci A. Compressor/ nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). Eur. Rev. Med. Pharmacol. Sci. 2007, v. 11, p. 225-237.Bousquet J., Delacourt C. Introduction. Nebulized beclometasone dipropionate therapy in asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S1-S4.Poli G., Acerbi D. Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. Respir. Med. 2003, v 97 (Suppl. B), p. S5-S9.Delacourt C., Dutau G., Lefrançois G., Clerson P. on behalf of the Beclospin Clinical Development Group. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S27-33.Terzano C., Allegra L., Barkai L., Cremonesi G. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur. Rev. Med. Pharmacol. Sci. 2001, v. 5, p. 17-24.Terzano C., Ricci A., Burinschi V., Nekam K., Lahovsky J. Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S35-S40.Bousquet J., Meziane H., Chanez P. et al. The response of two different dosages of beclometasone dipropionate suspension for nebulization versus a standard dose of beclometasone dipropionate via a metered-dose inhaler on bronchoprovocation testing in adults with asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S11-S14.Marcus P., Oppenheimer E.A., Patel P.A. et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann. Allergy Asthma Immunol. 2006, v. 96, p. 736-743.Otulana B.A., Varma N., Bullock A., Higgenbottam T.W. High dose nebulized steroid in the treatment of steroid-dependent asthma. Respir. Med. 1992, v. 86, p. 105-108.Higgenbottam T.W., Clark R.A., Luksza A.R. et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur. J. Clin. Res. 1994, v. 5, p. 1-10.Conolly K.C., Peake M.D., Halpin D.M.G. et al. on behalf of the Astra Pharmaceuticals Research Group. Challenging current asthma treatment guidelines. Improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Dis. Manage Health Outcomes. 2000, v. 7, p. 217-225.Grzelewska-Rzymowska I., Kroczynska-Bednarek J., Zarkovic J. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S21-S26.Higgenbottam T.W., Britton J., Lawrence D. et al. On behalf of the Pulmicort® Respules versus oral steroids: A prospective clinical trial in acute asthma. Comparison of nebulised budesonide and prednisolone in severe asthma exacerbation in adults. BioDrugs. 2000, v. 14, p. 247-254.Авдеев С.Н., Жестков А.В., Лещенко И.В. и соавт. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование. Пульмонология. 2006, № 4, с. 58-67.Reddel H.K., Taylor D.R., Bateman E.D. et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice. Am. J. Respir. Crit. Care Med. 2009, v. 180, p. 59-99.Gawchik S.M. Successful treatment of previously uncontrolled adult asthma with budesonide inhalation suspension: five-year case histories. Ann. Pharmacother. 2007, v. 41, p. 1728-1733.Marcus P. Budesonide inhalation suspension in adults with poorly controlled asthma or chronic obstructive pulmonary disease. J. Appl. Res. 2009, v. 9, p. 3-13.Bisca N., Cernatescu I., Dragomir D. et al. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir. Med. 2003, v. 97 (Suppl. B), p. S15-S20.